Loading
AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix. May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Vemurafenib.
In plain words · AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix.
No product in this corpus aims at AEBP1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA AEBP1: RNA tissue enriched (blood vessel 1,145 nTPM); blood lineage lineage enriched (dendritic cells 8 nTPM); high antibody staining in 3 normal tissues; highest cancer staining melanoma (5 of 10 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas AEBP1 tissue; Open Targets ENSG00000106624 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Ohno et al, Biochem. Biophys. Res. Commun, 1996, "A cDNA cloning of human AEBP1 from primary cultured osteoblasts and its expression in a differentiating osteoblastic cell line". Source.
Sources: HGNC HGNC:303 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8IUX7 (protein name, function text, keywords and locations (REST API)); CIViC gene AEBP1 (1 evidence items, 0 assertions, 1 variants; diseases: Skin Melanoma (GraphQL API, CC0))
As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix. May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness. Can act as a transcriptional repressor. Location: Secreted; Cytoplasm; Nucleus (UniProt). Locus 7p13 (HGNC).
RNA: tissue enriched (blood vessel 1,145 nTPM), detected in all normal tissues. Blood: lineage enriched (dendritic cells 8 nTPM).
Medium: Gallbladder, Rectum, Small intestine, Stomach.
RNA cancer enhanced: Skin Cutaneous Melanoma 691 pTPM.
Medium only: breast cancer, colorectal cancer, endometrial cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"AEBP1" OR ABSTRACT:"AEBP1" OR TITLE:"AE binding protein 1" OR ABSTRACT:"AE binding protein 1" OR TITLE:"Adipocyte enhancer-binding protein 1" OR ABSTRACT:"Adipocyte enhancer-binding protein 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AEBP1, not a curated reading list.